| 2024-02 |
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial |
Journal of Clinical Oncology
|
| 2024-01 |
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma |
Cancer Research and Treatment
|
| 2023-12 |
Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer |
Lung Cancer
|
| 2023-11 |
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC |
JTO Clinical and Research Reports
|
| 2023-08 |
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial |
Cancer Medicine
|
| 2023-07 |
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy |
Translational Lung Cancer Research
|
| 2023-06 |
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study |
Lung Cancer
|
| 2023-04 |
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing |
Cancer Research and Treatment
|
| 2023-03 |
Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea |
Drugs Real World Outcomes
|
| 2023-03 |
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC |
JTO Clinical and Research Reports
|
| 2023-03 |
The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer |
The Korean Journal of Internal Medicine
|
| 2023-02 |
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation |
CANCER
|
| 2023-02 |
Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity |
Yonsei Medical Journal
|
| 2023-01 |
Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea |
Palliative Medicine Reports
|
| 2023-01 |
Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01) |
Cancers
|
| 2022-12 |
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy |
Therapeutic Advances in Medical Oncology
|
| 2022-12 |
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study |
CLINICAL LUNG CANCER
|
| 2022-12 |
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment |
FRONTIERS IN CHEMISTRY
|
| 2022-12 |
Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer |
Radiation Oncology
|
| 2022-12 |
Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck |
RADIATION ONCOLOGY
|
| 2022-09 |
Regulatory T cells in the tumour microenvironment of head and neck cancer: Emerging target in the era of immunotherapy |
Clinical and Translational Discovery
|
| 2022-07 |
Neoadjuvant Immunotherapy following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes |
Korean Journal of Otorhinolaryngology Head and Neck Surgery
|
| 2022-05 |
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation |
THERANOSTICS
|
| 2022-05 |
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience |
CANCER IMMUNOLOGY IMMUNOTHERAPY
|
| 2022-04 |
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors |
JOURNAL OF THORACIC ONCOLOGY
|
| 2022-04 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials |
Journal for ImmunoTherapy of Cancer
|
| 2022-04 |
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) |
Lung Cancer
|
| 2022-03 |
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice |
CURRENT ONCOLOGY
|
| 2022-03 |
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice |
CLINICAL CANCER RESEARCH
|
| 2022-03 |
Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy |
RADIOTHERAPY AND ONCOLOGY
|
| 2022-03 |
Disproportional enrichment of FoxP3(+)CD4(+) regulatory T cells shapes a suppressive tumourmicroenvironment in head and neck squamous cell carcinoma |
Clinical and translational medicine
|
| 2022-03 |
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges |
FRONTIERS IN ONCOLOGY
|
| 2022-02 |
Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models |
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
|
| 2022-02 |
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma |
New England Journal of Medicine
|
| 2022-02 |
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy |
Immune Network
|
| 2022-01 |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01) |
Cancer Research and Treatment
|
| 2022-01 |
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models |
Clinical & Translational Immunology
|
| 2022-01 |
The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer |
Experimental and Molecular Medicine
|
| 2022-01 |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01) |
The Korean Journal of Internal Medicine
|
| 2022-01 |
Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy |
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
|
| 2021-12 |
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck |
ESMO OPEN
|
| 2021-12 |
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial |
JOURNAL OF THORACIC ONCOLOGY
|
| 2021-12 |
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort |
JOURNAL OF THORACIC ONCOLOGY
|
| 2021-12 |
Human reference gut microbiome catalog including newly assembled genomes from under-represented Asian metagenomes |
GENOME MEDICINE
|
| 2021-11 |
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma |
JOURNAL OF CLINICAL INVESTIGATION
|
| 2021-11 |
두경부암의 최신 표적치료 |
대한두경부종양학회지
|
| 2021-10 |
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. |
Journal for ImmunoTherapy of Cancer
|
| 2021-10 |
Role and Function of O-GlcNAcylation in Cancer |
Cancers
|
| 2021-10 |
Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer |
NATURE COMMUNICATIONS
|
| 2021-10 |
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations |
INVESTIGATIONAL NEW DRUGS
|
| 2021-09 |
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer |
ANNALS OF ONCOLOGY
|
| 2021-09 |
Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients |
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
|
| 2021-08 |
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. |
EUROPEAN JOURNAL OF CANCER
|
| 2021-07 |
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12 |
CANCER RESEARCH AND TREATMENT
|
| 2021-07 |
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma |
CANCER MEDICINE
|
| 2021-07 |
Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study |
Cancers
|
| 2021-06 |
Distinct characteristics and clinical outcomes to predict the emergence of met amplification in patients with non-small cell lung cancer who developed resistance after treatment with epidermal growth factor receptor tyrosine kinase inhibitors |
Cancers
|
| 2021-06 |
Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy |
Cancers
|
| 2021-05 |
Clinical Insights Into Novel Immune Checkpoint Inhibitors |
FRONTIERS IN PHARMACOLOGY
|
| 2021-05 |
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 therapy in Non-Small Cell Lung Cancer |
MOLECULES AND CELLS
|
| 2021-04 |
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2021-04 |
Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients |
SCIENTIFIC REPORTS
|
| 2021-04 |
Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma |
SCIENTIFIC REPORTS
|
| 2021-03 |
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques |
FRONTIERS IN ONCOLOGY
|
| 2021-02 |
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma |
JOURNAL OF HEPATOLOGY
|
| 2021-01 |
Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer |
EUROPEAN JOURNAL OF CANCER
|
| 2020-12 |
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck |
BRITISH JOURNAL OF CANCER
|
| 2020-11 |
The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma |
JOURNAL OF THORACIC DISEASE
|
| 2020-11 |
Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33/ST2 signaling |
CANCER IMMUNOLOGY RESEARCH
|
| 2020-11 |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2020-10 |
Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma |
CANCER
|
| 2020-09 |
Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer |
EXPERIMENTAL AND MOLECULAR MEDICINE
|
| 2020-08 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) |
BMC CANCER
|
| 2020-08 |
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC |
CANCER DISCOVERY
|
| 2020-07 |
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small- cell lung cancer |
Journal for ImmunoTherapy of Cancer
|
| 2020-07 |
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade |
JCI insight
|
| 2020-07 |
Pembrolizumab or Placebo Plus Etoposide and platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study |
JOURNAL OF CLINICAL ONCOLOGY
|
| 2020-07 |
Prognostic value of cd200r1 mrna expression in head and neck squamous cell carcinoma |
Cancers
|
| 2020-07 |
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer |
CLINICAL CANCER RESEARCH
|
| 2020-06 |
The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression |
CANCER RESEARCH
|
| 2020-06 |
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer |
SCIENTIFIC REPORTS
|
| 2020-04 |
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response |
BRITISH JOURNAL OF CANCER
|
| 2020-04 |
Establishment and Characterization of Patient-Derived Xenografts as Paraclinical Models for Head and Neck Cancer |
BMC CANCER
|